Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 2/20 | 0.51 |
| ▸ | HSPA5 | P11021 | 6/20 | 0.47 |
| ▸ | HSPA8 | P11142 | 3/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.45 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HBB | P68871 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ATG7 | O95352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15746955 | 0.91 | HSPA5 (0.45) | HSPA5HSPA8RXFP1CDK5CDK5R1 | |
| SCHEMBL19007434 | 0.90 | HSPA5 (0.46) | HSPA5HSPA8RXFP1CDK5CDK5R1 | |
| SCHEMBL17918401 | 0.89 | HSPA8 (0.55) | ADKHSPA5HSPA8RXFP1CDK5 | |
| SCHEMBL23114970 | 0.87 | HSPA8 (0.40) | ADKHSPA5HSPA8RXFP1CDK5 | |
| SCHEMBL22315144 | 0.86 | ADORA3 (0.51) | ADKHSPA5HSPA8RXFP1CDK5 | |
| SCHEMBL18852628 | 0.84 | ADK (0.43) | ADKHSPA5ADORA3ATG7 | |
| SCHEMBL18464362 | 0.83 | ADK (0.57) | ADKHSPA5HSPA8RXFP1ADORA3 | |
| SCHEMBL18531148 | 0.79 | ENTPD1 (0.41) | ADKHSPA5ADORA3 | |
| SCHEMBL21276426 | 0.79 | PRMT5 (0.43) | — | |
| SCHEMBL14948817 | 0.76 | HSPA5 (0.42) | HSPA5ADORA3ATG7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210299278-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF BIOLOGICS AND PROTEINS ASSOCIATED WITH HUMAN DISEASE | MODERNATX, INC. | 2021-09-30 | — | — | US | disclosed |
| US-10772975-B2 | Modified Polynucleotides for the production of biologics and proteins associated with human disease | MODERNATX, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-9828416-B2 | Modified polynucleotides for the production of secreted proteins | MODERNATX, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9827332-B2 | Modified polynucleotides for the production of proteins | MODERNATX, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9790531-B2 | Enzymes and polymerases for the synthesis of RNA | MODERNATX, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170130255-A1 | ENZYMES AND POLYMERASES FOR THE SYNTHESIS OF RNA | MODERNATX, INC. (US) | 2017-05-11 | — | — | US | disclosed |
| US-9587003-B2 | Modified polynucleotides for the production of oncology-related proteins and peptides | MODERNATX, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9572897-B2 | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins | MODERNATX, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-20170028085-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS | MODERNATX INC (US) | 2017-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | ADK 414/4885HSPA5 1076/4885HSPA8 1345/4885 |
| US-20170028085-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS | POLN, POLRMT, MSH2 | ADK 2231/4885HSPA5 1404/4885HSPA8 1575/4885 |
| US-10772975-B2 | Modified Polynucleotides for the production of biologics and proteins associated with human disease | RNMT, RNGTT, SARNP | ADK 3514/4885HSPA5 474/4885HSPA8 2072/4885 |
| US-20210299278-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF BIOLOGICS AND PROTEINS ASSOCIATED WITH HUMAN DISEASE | POLRMT, POLN, POLM | ADK 2860/4885HSPA5 1364/4885HSPA8 1828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.